Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04705454 |
Expanded Access Status :
Available
First Posted : January 12, 2021
Last Update Posted : January 12, 2021
|
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) | Biological: Loncastuximab Tesirine |
Study Type : | Expanded Access |
Expanded Access Type : | Individual Patients |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Inclusion Criteria:
- Male or female patient aged 18 years or older
- Pathologic diagnosis of DLBCL
- Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) that cannot be treated by currently available drugs, cell therapy, or clinical trials
- Women of childbearing potential must agree to use a highly effective method of contraception from the time of giving informed consent until at least six months after the last dose of loncastuximab tesirine. Men with female partners who are of childbearing potential must agree that they will use a highly effective method of contraception from the time of giving informed consent until at least six months after the patient receives his last dose of loncastuximab tesirine
Exclusion Criteria:
- Known history of hypersensitivity to or positive serum human Anti-Drug Antibodies to loncastuximab tesirine
- Total bilirubin >1.5 x upper limit of normal (ULN)
- Active second primary malignancy other than non-melanoma skin cancers, nonmetastatic prostate cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast, or other malignancy that ADCT Head of Medical Affairs and/or designee, and treating physician agree and document should not be exclusionary
- Autologous Stem Cell Transplantation (SCT) within 30 days prior to start of loncastuximab tesirine
- Allogeneic SCT within 60 days prior to start of loncastuximab tesirine
- Clinically significant third space fluid accumulation (i.e., ascites requiring drainage or pleural effusion that is either requiring drainage or associated with shortness of breath)
- Lymphoma with active central nervous system involvement at the time of screening, including leptomeningeal disease
- Breastfeeding or pregnant
- Major surgery, radiotherapy, chemotherapy or other anti-neoplastic therapy within 14 days prior to starting loncastuximab tesirine, except shorter if approved by ADCT
- Use of any other experimental medication within 14 days prior to starting loncastuximab tesirine
- Any other significant medical illness, abnormality, or condition that would, in the treating physician's judgment, make the patient inappropriate to receive loncastuximab tesirine or put the patient at risk

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04705454
Contact: ADC Therapeutics Medical Affairs | (954) 903-7994 | eap@adctherapeutics.com |
Responsible Party: | ADC Therapeutics S.A. |
ClinicalTrials.gov Identifier: | NCT04705454 |
Other Study ID Numbers: |
ADCT-402 EAP |
First Posted: | January 12, 2021 Key Record Dates |
Last Update Posted: | January 12, 2021 |
Last Verified: | January 2021 |
Expanded Access Lymphoma Large B-Cell Relapsed Refractory |
Lymphoma Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type Neoplasms |
Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma, Non-Hodgkin |